D. Western Therapeutics Institute
4576
Needs Well
3992
Daiwa Cycle
5888
Osaka Yuka Industry
4124
Liberta
4935
(FY)Sep 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 16.90%73.79B | 17.09%18.31B | 20.07%17.79B | 25.49%63.12B | 20.81%16.12B | 28.29%16.55B | 28.19%15.64B | 24.92%14.81B | 20.71%50.3B | 19.85%13.34B |
Cost of revenue | 11.02%25.68B | 13.23%6.59B | 24.22%6.24B | 38.83%23.13B | 31.80%5.91B | 42.62%6.37B | 44.80%5.82B | 36.30%5.02B | 22.80%16.66B | 12.69%4.49B |
Gross profit | 20.30%48.1B | 19.38%11.72B | 17.94%11.55B | 18.88%39.99B | 15.25%10.2B | 20.70%10.17B | 20.02%9.82B | 19.79%9.79B | 19.71%33.64B | 23.84%8.85B |
Operating expense | 16.48%22.92B | 7.47%4.9B | 21.62%5.72B | 13.15%19.67B | 9.66%5.91B | 14.93%4.5B | 13.37%4.56B | 15.87%4.7B | 15.06%17.39B | 22.99%5.39B |
Selling and administrative expenses | 16.79%23.23B | 7.75%4.98B | 22.27%5.8B | 13.00%19.89B | 9.15%5.96B | 15.42%4.57B | 13.31%4.62B | 15.45%4.74B | 17.12%17.6B | 30.97%5.46B |
-General and administrative expense | 16.79%23.23B | 7.75%4.98B | 22.27%5.8B | 13.00%19.89B | 9.15%5.96B | 15.42%4.57B | 13.31%4.62B | 15.45%4.74B | 17.12%17.6B | 30.97%5.46B |
Other operating expenses | -45.05%46.07M | -48.24%6.35M | -99.75%58K | 38.17%83.85M | 116.98%41.56M | -71.55%7.26M | 51.65%12.26M | 169.47%22.77M | -82.32%60.69M | -93.90%19.15M |
Total other operating income | 19.40%361.94M | 16.22%84.54M | 26.63%82.74M | 8.72%303.13M | 1.55%87.58M | 11.16%77.47M | 14.90%72.74M | 8.72%65.34M | 5.75%278.82M | -11.99%86.24M |
Operating profit | 24.00%25.19B | 29.70%6.82B | 14.54%5.83B | 25.01%20.31B | 23.96%4.29B | 25.71%5.67B | 26.45%5.26B | 23.66%5.09B | 25.12%16.25B | 25.18%3.46B |
Net non-operating interest income (expenses) | 133.71%505.71M | 332.47%257.81M | 116.27%61.94M | -84.44%216.38M | 19.73%336.76M | -44.65%371.2M | -139.81%-110.9M | -337.69%-380.68M | 394.41%1.39B | 464.88%281.27M |
Non-operating interest income | 10.26%1.13B | 47.83%337.72M | 26.19%295.08M | -37.01%1.02B | -15.36%289.62M | -38.83%445.18M | -31.85%228.45M | 8.29%233.83M | 234.85%1.62B | 222.35%342.18M |
Non-operating interest expense | -22.93%620.23M | -76.45%79.92M | -62.06%233.14M | 249.13%804.77M | -177.40%-47.14M | 29.30%73.98M | 499.36%339.35M | 1,002.02%614.51M | 13.63%230.51M | 8.07%60.91M |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | 68.71%181.85M | 495.03%118.94M | 221.06%26.97M | -41.64%107.79M | 6,393.49%54.87M | -73.38%55.21M | 143.46%19.99M | -199.07%-22.27M | 975.95%184.7M | 101.53%845K |
Special income (charges) | 1.63B | 0 | 0 | 0 | 16.93B | 512.87M | ||||
Less:Other special charges | ---1.63B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---16.93B | ---512.87M |
Other non-operating income (expenses) | ||||||||||
Income before tax | 33.28%27.5B | 39.26%7.2B | 26.29%5.92B | -40.63%20.64B | 10.01%4.68B | -72.04%6.1B | 17.68%5.17B | 9.03%4.69B | 161.61%34.76B | 54.23%4.26B |
Income tax | 21.37%8.27B | 56.59%2.19B | 7.11%2.32B | -34.46%6.81B | 38.55%1.65B | -73.95%1.6B | 2.96%1.4B | 26.05%2.16B | 141.60%10.4B | 40.97%1.19B |
Net income | 39.15%19.24B | 32.83%5.01B | 42.73%3.6B | -43.26%13.82B | -1.12%3.03B | -71.29%4.5B | 24.28%3.77B | -2.28%2.52B | 171.19%24.36B | 60.10%3.06B |
Net income continuous operations | 39.15%19.24B | 32.83%5.01B | 42.73%3.6B | -43.26%13.82B | -1.12%3.03B | -71.29%4.5B | 24.28%3.77B | -2.28%2.52B | 171.19%24.36B | 60.10%3.06B |
Noncontrolling interests | 52.44%529.63M | 43.81%125.7M | 102.19%154.27M | 66.24%347.44M | 71.53%67.88M | 58.75%115.85M | 180.23%87.41M | 16.93%76.3M | 27.33%209M | 25.55%39.58M |
Net income attributable to the company | 38.81%18.71B | 32.57%4.88B | 40.88%3.45B | -44.21%13.48B | -2.07%2.96B | -71.90%4.39B | 22.66%3.68B | -2.78%2.45B | 173.87%24.15B | 60.68%3.02B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 38.81%18.71B | 32.57%4.88B | 40.88%3.45B | -44.21%13.48B | -2.07%2.96B | -71.90%4.39B | 22.66%3.68B | -2.78%2.45B | 173.87%24.15B | 60.68%3.02B |
Gross dividend payment | ||||||||||
Basic earnings per share | 38.80%246.62 | 32.54%64.35 | 40.87%45.46 | -44.20%177.68 | -2.06%39.03 | -71.90%57.84 | 22.66%48.55 | -2.77%32.27 | 169.92%318.45 | 61.27%39.85 |
Diluted earnings per share | 38.66%243.85 | 32.40%63.62 | 40.73%44.99 | -44.11%175.86 | -2.13%38.63 | -71.83%57.21 | 22.58%48.05 | -2.83%31.97 | 170.86%314.66 | 60.51%39.47 |
Dividend per share | 116 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 46.30%79 | 46.30%79 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |